BusinessImmuron Progresses Discussions with Institutional FundsBy Nasdaq OMXMar 13, 2018, 1:30 PM UTC
BusinessGalectin Therapeutics Announces Results from Phase 2b NASH-CX TrialBy Nasdaq OMXDec 5, 2017, 1:15 PM UTC
BusinessGalectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017By Nasdaq OMXDec 4, 2017, 9:00 PM UTC
BusinessProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic FibrosisBy Nasdaq OMXSep 25, 2017, 8:00 PM UTC
BusinessBrainsway® Announces Positive Final Results of its Deep TMS Multicenter Study in Obsessive Compulsive Disorder (OCD) PatientsBy Nasdaq OMXJun 12, 2017, 4:35 PM UTC
BusinessNew Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1By Nasdaq OMXApr 18, 2017, 10:30 AM UTC
BusinessProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis PatientsBy Nasdaq OMXOct 27, 2016, 11:05 AM UTC
BusinessProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis PatientsBy Nasdaq OMXOct 27, 2016, 11:05 AM UTC
